Chai Discovery builds a computer-aided design suite for molecules, using generative AI models that learn biochemical structure and interaction to design new molecules from scratch. Its models, including Chai-2 and Chai-3, support antibody and molecular design for pharmaceutical and life sciences discovery teams, with customers including Novartis, Pfizer, Eli Lilly and argenx. The company was founded in 2024 and is based in San Francisco, California.